Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 10/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29915550 | 0.82 | EPAS1 (0.47) | EPAS1TRPA1L3MBTL1HSPB1MAPK14 | |
| SCHEMBL21634034 | 0.82 | EPAS1 (0.47) | EPAS1TRPA1L3MBTL1HSPB1MAPK14 | |
| SCHEMBL21633965 | 0.82 | EPAS1 (0.47) | EPAS1TRPA1L3MBTL1HSPB1MAPK14 | |
| SCHEMBL28388159 | 0.78 | EPAS1 (0.55) | EPAS1TRPA1L3MBTL1HSPB1 | |
| SCHEMBL20384414 | 0.78 | EPAS1 (0.55) | EPAS1SLC6A4TRPA1L3MBTL1HSPB1 | |
| SCHEMBL21652832 | 0.77 | PKM (0.47) | EPAS1HSPB1 | |
| SCHEMBL29915547 | 0.77 | PKM (0.47) | EPAS1HSPB1 | |
| SCHEMBL23403939 | 0.77 | PKM (0.44) | EPAS1TRPA1HSPB1MAPK14 | |
| SCHEMBL21633979 | 0.77 | EPAS1 (0.43) | EPAS1L3MBTL1BRD4MAPK14 | |
| SCHEMBL21652794 | 0.76 | EPAS1 (0.48) | EPAS1TRPA1HSPB1BRD4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| EP-3828183-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020020288-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | BRD1, BRD4, BRD2 | EPAS1 3006/4885SLC6A4 4767/4885TRPA1 4591/4885 |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | BRD4, BRD1, BRD3 | EPAS1 2836/4885SLC6A4 4838/4885TRPA1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.